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ABSTRACT 
Curcumin (diferuloylmethane) is a natural polyphenolic compound with potent anti-inflammatory, anticancer and antioxidant 
activities. However, its bioavailability is low as it is poorly absorbed in the gastrointestinal tract. Microemulsions offer the potential 
to improve the solubility and bioavailability of bioactive compounds; the present work investigated the topical delivery potential of 
microemulsion gel loaded with curcumas. Curcumin microemulsion was prepared by spontaneous emulsification method using oil 
(Oleic acid), surfactant:cosurfactant (S
mix
) (Ethanol and Tween 80, Span 80 and n Butanol) and water. The optimized formulations of 
microemulsions were subjected to thermodynamic stability tests. After stability study, stable formulation was characterized for 
droplet size, pH determination, centrifugation, % drug content in microemulsion, zeta potential and vesicle size measurement and 
then microemulsion gel were prepared and characterized for spreadability, measurement of viscosity, drug content, In-vitro 
diffusion, in-vitro release data. Tween 80, Span 80 was selected as surfactant, ethanol, n Butanol as co surfactant and Oleic acid as 
oil component based on solubility study. The optimized formulation contained Curcumin (10 mg). The in vitro drug release from 
curcumin microemulsion gel was found to be considerably higher in comparison to that of the pure drug. The in-vitro diffusion of 
microemulsion gel was significantly good. Based on this study, it can be concluded the solubility and permeability of curcumin can 
be increased by formulating into microemulsion gel. 
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Curcumin is a yellow hydrophobic polyphenol derived 
from the rhizome of the herb Curcuma longa (family 
Zingiberaceae) is a diferuloylmethane [1,7-Bis(4-
hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] 
and has been used for centuries as a spice in the Indian 
subcontinent 
1
. Conventionally, it has been used for 
many conditions, particularly as an anti-inflammatory 
agent 
2
. Curcumin also possesses antiviral, antibacterial, 
antifungal, antioxidant, antiparasitic, antitumoral, and 
anticarcinogenic activities. Additionally, it is considered 
a hepato-, nephro-, and myocardial infarction- protector 
3. It has also been established that curcumin displays 
antirheumatic and immunomodulatory activities. These 
effects are mediated through the regulation of various 
transcription and inflammatory cytokines, protein 
kinases, growth factors, and other enzymes 
4
. The 
pharmacological safety and efficacy of curcumin makes 
it a potential compound for treatment and prevention of 
a wide variety of chronic illnesses, diabetes, allergies, 
arthritis, and Alzheimer’s disease 5. Similarly, the 
efficacy of curcumin in various malignant diseases 
including cancer has been established 
6
. Nevertheless, 
the poor bioavailability of curcumin has been underlined 
as a major drawback. The first reported study that 
examined the uptake of curcumin using Sprague-Dawley 
rats showed negligible amounts of curcumin in the rat’s 
blood plasma after oral administration of 1 g/kg of 
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curcumin, suggesting that curcumin was poorly absorbed 
from the GIT 
7
. Recently, nanotechnological delivery 
systems for drugs and nutraceuticals have emerged as 
promising solutions to improve the bioavailability of 
therapeutic agents and bioactive compounds 
8
. Several 
nanoformulations of curcumin have been extensively 
investigated over the last decade like liposomes, 
nanoparticles, nanoconjugates, and microemulsions, 
which have been aimed at enhancing bioavailability by 
solubilization or encapsulation thus protecting against 
hydrolysis and achieving sustained release at the site of 
targeting 
9-14
. Microemulsion as a topical carrier system 
is very suitable with merits like low skin irritation, 
excellent permeation, and high drug-loading capacity as 
compared to other colloidal carriers 
15, 16
. However, due 
to low retention at the site of application by virtue of low 
viscosity of microemulsion system and inconvenient 
application, it is often converted into a gel form 
17-20
. 
Osteoarthritis is characterized by the breakdown of 
cartilage, joint lining, ligaments and underlying bone.
1-3
 
It typically involves an entire joint, with the most 
commonly affected joints being the knees, hips, hands, 
and spine. Common manifestations of osteoarthritis are 
pain and stiffness. There are a variety of risk factors for 
osteoarthritis, including obesity, high impact Sports, and 
bone deformities. The prevalence of osteoarthritis 
increases with age 
21-23
. 
Hence, in the present study a gel based Microemulsion 
system loaded with curcumin intended to be used as 
adjunct therapy for the treatment of Osteoarthritis was 
developed and evaluate the effect of varying the 
composition, entrapment efficiency, curcumin 
concentration, Zeta potential, vesicle size and stability 
studies.  
MATERIALS AND METHOD  
The sample of curcumin used in this study was supplied 
by Sigma Aldrich (MKE, USA). Ethanol, methanol, 
analytical grade Tween 80 and Span 80 were purchased 
from Merck (MA, USA). Oleic acid, Carbopol 934 and n 
Butanol was purchased from S. D. Fine Chem. Ltd., 
Mumbai. All other surfactant and co surfactant were 
purchased from Hi Media, Mumbai. Double distilled 
water was prepared freshly and used whenever required. 
All other chemicals used in this study including those 
stated were of analytical reagent (A.R.) grade. 
Solubility studies 
Solubility determination in the various oils, surfactants 
and co-surfactants for formulating microemulsion drug 
delivery system.  The solubility of the drug in different 
oils is an essential step for the microemulsion 
formulation. So before starting the phase diagram one 
must have to select the oil, surfactant and co-surfactant 
in which the drug shows maximum solubility, to be in 
the desired solubility range, which is essential for the 
formulation of microemulsion drug delivery system. 
Formulation of Curcumin -loaded microemulsion 
Eight different formulations has been selected by 
keeping the total quantity of the formulation  constant as 
100% and varying all components of the system. Each 
formulation has been loaded with Curcumin of 10mg/ml.  
All eight formulations have been evaluated for different 
parameters such as pH, In-vitro release and solubility 
(Table 1). 
Table 1: Formulation composition of prototype formulations 
Formulation code Drug Oil  
(Ratio) 
Surfactant: Co-surfactants  
(Smix ratio) 
F1 10 1 1:2 
F2 10 1 1:3 
F3 10 1 1:4 
F4 10 1 1:5 
F5 10 1 1:6 
F6 10 1 1:7 
F7 10 1 1:8 
F8 10 1 1:9 
 
Evaluation of Formulations 
pH Determination 
The pH of each formulation was found before and after dilution by using pH meter Table-2. 
Table 2: Results of pH of Curcumin loaded microemulsion 
S. No. Formulation code pH* 
1 F1 6.98±0.02 
2 F2 7.01±0.01 
3 F3 6.99±0.02 
4 F4 7.01±0.02 
5 F5 6.98±0.02 
6 F6 6.99±0.03 
7 F7 6.65±0.01 
8 F8 6.66±0.02 
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Centrifugation 
This parameter characterized to check the physical 
stability of formulation. The microemulsion system was 
centrifuged at 5000 rpm for 10 minutes to determine 
whether the system shows signs of creaming or phase 
separation. The system was observed visually for 
appearance Table-3. 
Determination of % Drug Content in microemulsion 
The mixture (Microemulsion) was centrifuged at 1000 
rpm for 15 min, 0.2 ml of supernatant was taken and 
diluted with 0.1 N HCL. Absorbance was measured at 
428nm by UV Spectrophotometer. Concentration of 
Curcumin was determined using standard curve 
equation and % drug content was calculated Table-3. 
 
Table 3: Results of Centrifugation and % Drug Content in microemulsion 
Formulation Code  Centrifugation % Drug Content in microemulsion* 
F1 Translucent 75.65±0.45 
F2 Translucent 74.56±0.36 
F3 Translucent 69.98±0.21 
F4 Transparent 71.45±0.25 
F5 Transparent 75.65±0.14 
F6 Transparent 83.32±0.15 
F7 Transparent 80.14±0.25 
F8 Transparent 75.01±0.32 
*Average of three determinations 
 
Zeta Potential and Vesicle size  
Zeta Potential of samples was measured by Zetasizer. 
Samples were placed in clear disposable zeta cells and 
results were recorded (Fig 1&2). 
 
Figure 1: Result of Zeta Potential of Optimized Batch 
F6 (-32.4mV) 
 
Figure 2: Result of Vesicle size of Optimized Batch 
Preparation of carbopol gel base: 0.5 g Carbopol 934 
was weighed and dispersed in water with mild stirring 
and allowed to swell for 24 hours to obtain 0.5% gel. 
Later 2 ml of glycerin was added to for gel consistency. 
Similarly 1 and 2% carbopol gels were prepared. 
Preparation of microemulsion gel: Equivalent to 1g of 
microemulsion formulation was dissolved in 10ml of 
ethanol and centrifuged at 6000 rpm for 20 minutes to 
remove the unentrapped drug. The supernant was 
decanted and sediment was incorporated into the gel 
vehicle.The incorporation of the microemulsion into gels 
was achieved by slow mechanical mixing at 25 rpm for 
10 minutes. The optimized formulation was incorporated 
into three different gel concentration 0.5, 1 and 2% w/w 
(Table-4). 
Table 4: Composition of different gel base 





Evaluation of Gel 
Determination of pH: Weighed 50 gm of gel 
formulation were transferred in 10 ml of beaker and 
measured it by using the digital pH meter. pH of the 
topical gel formulation should be between 6–7 to treat 
the skin infections. 
Spreadability: A modified apparatus suggested was 
used for determining spreadability. The spreadability 
was measured on the basis of slip and drag 
characteristics of the gels. The modified apparatus was 
fabricated and consisted of two glass slides, the lower 
one was fixed to a wooden plate and the upper one was 
attached by a hook to a balance. The spreadability was 
determined by using the formula: S=ml/t, where S, is 
spread ability, m is weight in the pan tied to upper slide 
and t is the time taken to travel a specific distance and l 
is the distance traveled. For the practical purpose the 
mass, length was kept constant and‘t’ was determined.  
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The measurement of spreadability of each formulation 
was in triplicate and the average values are presented. 
Measurement of viscosity: The viscosity of gels was 
determined by using a Brook Field viscometer DV-II 
model. A T-Bar spindle in combination with a helipath 
stand was used to measure the viscosity and have 
accurate readings.  
The T-bar spindle (T95) was used for determining the 
viscosity of the gels. The factors like temperature, 
pressure and sample size etc. which affect the viscosity 
were maintained during the process. The helipath T- bar 
spindle was moved up and down giving viscosities at 
number of points along the path. The torque reading was 
always greater than 10%. Five readings taken over a 
period of 60 sec. were averaged to obtain the viscosity. 
Drug content: Equvalant to 10mg (Curcumin) of the 
prepared gel was mixed with 100 ml. of ethyl alcohol. 
Aliquots of different concentrations were prepared by 
suitable dilutions after filtering the stock solution and 
the absorbance was measured at 242 nm. Drug content 
was calculated by linear regression analysis of the 
calibration curve (Table-5). 
  
Table 5: Results of microemulsion gel formulations 
 Code Drug content 
 (%) 




F1 98.15± 0.021 6.98±0.021 18.32±0.075 5898±15 
F2 98.05 ± 0.021 7.10±0.040 17.56±0.042 5945±23 
F3 99.45 ±0.027 7.05±0.060 16.95±0.059 6123±45 
 
In-vitro diffusion study: An in-vitro drug release study 
was performed using modified Franz diffusion cell. 
Dialysis membrane (Hi Media, Molecular weight 5000 
Daltons) was placed between receptor and donor 
compartments. Microemulsion gel equivalent to 5mg of 
drug was placed in the donor compartment and the 
receptor compartment was filled with phosphate buffer, 
pH 7.4 (24 ml). The diffusion cells were maintained at 
37±0.5°C with stirring at 50 rpm throughout the 
experiment. At different time interval, 5 ml of aliquots 
were withdrawn from receiver compartment through 
side tube and analyzed for drug content by UV Visible 
spectrophotometer (Table-6). 
  
Table 6: Interpretation of diffusional release mechanisms 
Release exponent (n) Drug transport mechanism Rate as a function of time 
0.5 Fickian diffusion t
-0.5
 
0.5<n<1.0 Anomalous transport t
n - 1
 
1.0 Case-II transport Zero-order release 




Mathematical treatment of in-vitro release data: The 
quantitative analysis of the values obtained in 
dissolution/release tests is easier when mathematical 
formulas that express the dissolution results as a 
function of some of the dosage forms characteristics are 
used Table-7-9. 
Zero-order kinetics: The pharmaceutical dosage forms 
following this profile release the same amount of drug 
by unit of time and it is the ideal method of drug release 
in order to achieve a pharmacological prolonged action. 
The following relation can, in a simple way, express this 
model Fig-3: 
Qt = Qo + Ko t 
where Qt is the amount of drug dissolved in time t, Qo is 
the initial  amount of drug in the solution (most times, 
Qo=0) and Ko is the zero order release constant (Bourne, 
2002). 
First-order kinetics: The following relation expresses 
this model: 
 
where Qt is the amount of drug dissolved in time t, Qo is 
the initial  amount of drug in the solution and K1 is the 
zero order release constant Table-10. 
In this way a graphic of the decimal logarithm of the 
released amount of drug versus time will be linear. The 
pharmaceutical dosage forms following this dissolution 
profile, such as those containing water-soluble drugs in 
porous matrices, release drug in a way that is 
proportional to the amount of drug remaining in its 
interior, in such way, that the amount of drug released 
by unit of time diminish Fig-4. 
Higuchi model: Higuchi developed several theoretical 
models to study the release of water-soluble and low 
soluble drugs in semi-solid and/or solid matrixes. 
Mathematical expressions were obtained for drug 
particles dispersed in a uniform matrix behaving as the 
diffusion media. The simplified Higuchi model is 
expressed as: 
 
Where Q is the amount of drug released in time t and KH 
is the Higuchi dissolution constant. Higuchi model 
describes drug release as a diffusion process based in the 
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Fick’s law, square root time dependent. This relation 
can be used to describe the drug dissolution from several 
types of modified release pharmaceutical dosage forms 
such as transdermal systems and matrix tablets with 
water-soluble drugs. 
Korsmeyer-Peppas model: Korsmeyer et al. used a 
simple empirical equation to describe general solute 
release behaviour from controlled release polymer 
matrices:  
 
Where Mt/M is fraction of drug released, a is kinetic 
constant, t is release time and n is the diffusional 
exponent for drug release. ’n’ is the slope value of log 
Mt/M  versus log time curve. Peppas stated that the 
above equation could adequately describe the release of 
solutes from slabs, spheres, cylinders and discs, 
regardless of the release mechanism. Peppas used this n 
value in order to characterize different release 
mechanisms, concluding for values for a slab, of n =0.5 
for fickian diffusion and higher values of n, between 0.5 
and 1.0, or n =1.0, for mass transfer following a non-
fickian model. In case of a cylinder n =0.45 instead of 
0.5, and 0.89 instead of 1.0. This equation can only be 
used in systems with a drug diffusion coefficient fairly 
concentration independent. To the determination of the 
exponent n the portion of the release curve where Mt/M  
< 0.6 should only be used. To use this equation it is also 
necessary that release occurs in a one-dimensional way 
and that the system width-thickness or length-thickness 
relation be at least 10. A modified form of this equation 
was developed to accommodate the lag time (l) in the 
beginning of the drug release from the pharmaceutical 
dosage form: 
 
When there is the possibility of a burst effect, b, this 
equation becomes: 
 
In the absence of lag time or burst effect, l and b value 
would be zero and only at
n 
is used. This mathematical 
model, also known as Power Law, has been used very 
frequently to describe release from several different 
pharmaceutical modified release dosage forms. 
 











% Drug Release 
Cumulative 
%  Drug 
Remaining 
Log Cumulative % 
Drug Remaining 
0.5 0.707 -0.301 13.560 1.132 86.440 1.937 
1 1.000 0.000 32.560 1.513 67.440 1.829 
2 1.414 0.301 65.560 1.817 34.440 1.537 
4 2.000 0.602 75.580 1.878 24.420 1.388 
6 2.449 0.778 76.200 1.882 23.800 1.377 
8 2.828 0.903 76.210 1.882 23.790 1.376 
*Average of three readings 














%  Drug 
Remaining 
Log Cumulative % 
Drug Remaining 
0.5 0.707 -0.301 20.250 1.306 79.750 1.902 
1 1.000 0.000 45.580 1.659 54.420 1.736 
2 1.414 0.301 68.890 1.838 31.110 1.493 
4 2.000 0.602 73.250 1.865 26.750 1.427 
6 2.449 0.778 73.560 1.867 26.440 1.422 
8 2.828 0.903 74.150 1.870 25.850 1.412 
*Average of three readings 



















0.5 0.707 -0.301 18.890 1.276 81.110 1.909 
1 1.000 0.000 38.890 1.590 61.110 1.786 
2 1.414 0.301 42.560 1.629 57.440 1.759 
4 2.000 0.602 54.650 1.738 45.350 1.657 
6 2.449 0.778 69.980 1.845 30.020 1.477 
8 2.828 0.903 87.980 1.944 12.020 1.080 
*Average of three readings 
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Figure 3: Cumulative % drug released Vs Time  
 
 
Figure 4: Log cumulative % drug remaining Vs Time 
 
Table 10: Regression analysis data of optimized 
formulation 
Batch 
Zero Order First Order 
R² R² 
F3 0.952 0.923 
 
Stability studies 
Curcumin loaded microemulsion gel was prepared and 
stored for 2 months first at cold condition (2ºC – 8ºC), 
room temperature and at elevated temperature (50º 
±2ºC) and evaluated by visual inspection (phase 
separation).  
RESULTS AND DISCUSSION 
The preliminary study showed that curcumin is yellow, 
aromatic, bitter powder. It is freely soluble in ethanol, 
methanol, soluble in 0.1 N NaoH and 7.2 pH phosphate 
buffer and insoluble in water, chloroform and 0.1 N 
HCl. The melting point was in the range of 182-184
0
C 
which is in compliance with the standard value of 183
0
C 
as per Indian Pharmacopoeia. From the FT-IR data of 
the physical mixture it is clear that functionalities of 
drug have remained unchanged including intensities of 
the peak. On the basis of above study it was concluded 
that the solubility in the oils, surfactants and co 
surfactants like Span 40, Span 80, Tween 20, Tween 80, 
Pluronic F-127, Castor Oil was found to be soluble and 
Sunflower Oil, Oleic acid was found to be slightly 
soluble  for the microemulsion preparation of curcumin. 
Different physicochemical properties of the selected oils 
were studied and were found to be favourable for 
microemulsion drug delivery system. The Vesicle size 
analysis of the optimized formulation F6 was done using 
particle size analyzer (Horiba).The mean Vesicle size 
was found to be 41.6nm. Zeta potential of the optimized 
formulation F6 was determined using particle size 
analyzer (Horiba). Zeta potential of optimized 
formulation was found to be -32.4mV. Drug content is 
most important in microemulsion formulation and the 
data found are satisfactory. It was found to be 
69.98±0.21to 83.32±0.15% which shows the good 
capacity of formulation to hold the drug. Three Different 
carbopol gel base prepared for optimization (0.5%, 1.0% 
and 2%) and evaluated for pH, spreadibility, viscosity 
measurements and in vitro drug release studies. The 
spreadability was measured on the basis of slip and drag 
characteristics of the gels and was in the range of 
16.95±0.059– 18.32±0.075gms. cm. /sec. In vitro drug 
release study of Optimized formulation was carried out 
using modified franz Diffusion cell. The optimized 
formulation F6 showed the maximum 83.32±0.15% drug 
release in 8 hrs. 
CONCLUSIONS 
Studies on phase behavior for optimization of 
microemulsion properties are important when low-
energy emulsification method is used, because the 
phases involved during emulsification are determinant in 
order to obtain microemulsions of small and uniform 
droplet size.All the prepared formulations exhibited the 
microemulsion properties. The optimized formulation 
was evaluated for zeta potential, globule size analysis 
and stability study. The results suggest that the 
optimized formulation was stable and produced 
microemulsion. The in-vitro diffusion study of the 
formulation was higher as compared to pure drug, 
indicating that the prepared formulation is having higher 
solubility and permeability. Thus it can be concluded 
that microemulsion formulation can be used as a one of 
the formulation technique to enhance the bioavailability 
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